Nano Geneeskunde...Nano Medicína
QBI Life Sciences uses Nanotechnology to advance Drug Discovery
WI, August 10, 2005 --- Long interested in advancing
the process of discovering new treatments for human
diseases, the principals of QBI Life Sciences today
announced the release of a second polymeric micelle
Polymeric Micelles. PreserveX™ Polymeric Micelles,
useful in working with difficult to handle proteins
average 21 nanometers in diameter. In the presence
of native cell membrane fractions, PreserveX™ Polymeric
Micelles self-assemble embedding pieces of cellular
membranes in the complex creating multiple particles
each providing an environment similar to that of
the native membrane. Below is an illustration of
This graphic illustrates the
use of PreserveX™ Polymeric
Micelles to solubilize membrane proteins and associated
lipids from membrane fractions resulting in stabilized
micelle/protein/lipid complexes. Copyright © QBI
newly released product, PreserveX™-QML-B Polymeric
Micelles contains a biotin label enabling the placement
of the micelle/protein/lipid complex onto a solid support
such as a protein microarray. Below is an illustration
of complexes immobilized on a solid support.
This graphic illustrates the
use of PreserveX™-QML-B
to immobilize the biotin-labeled micelle/protein/lipid
complexes on a surface (bar at the bottom of the
graphic) with the use of streptavidin. Once immobilized,
ligand binding or enzymatic activity can be determined,
or the presence of the protein can be confirmed.
Copyright © QBI Life Sciences
Micelles reflect the combination of polymer chemistry
technologies with protein chemistry technologies.
Vladimir Trubetskoy, Ph.D., Director of Polymer Chemistry
has headed up a team at QBI Life Sciences to develop
polymer nano-particles that are useful in working
with some of the most difficult to handle proteins.
Focusing on membrane proteins (those proteins that
reside on, near or embedded in cellular membranes),
Dr. Trubetskoy and his team of scientists have come
up with a set of very valuable drug discovery tools.
In the area of human health, membrane proteins represent
70% of all known drug targets, the agents inside
the human body upon which drugs evoke a therapeutic
effect. To date, efforts to study these proteins
and develop drugs targeting these proteins have been
Announcement of the introduction of PreserveX™-QML-B is coincident with a presentation
of product performance at the 2005 Drug Discovery Technology® & Development
World Congress in Boston, Massachusetts ( link ).
About QBI Life Sciences:
QBI Life Sciences is a division of Quintessence Biosciences, Inc. QBI Life
Sciences is focused on development and supply of research tools focused on
work with membrane proteins. The aim of the Company's product development
efforts is to enable new areas of research.
For more information, please visit www.qbilifesci.com
story has been adapted from a news release
Diese Meldung basiert auf einer Pressemitteilung -
tekst is gebaseerd op een nieuwsbericht -
the wave ?
some news ?
click on archive photo
how about joining us
contacting us ?